By Nancy Lapid
(Reuters) – The following is a roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19, the illness caused by the virus.
COVID-19 post-vaccination may be less contagious
People who get a COVID-19 vaccine can still become infected with the novel coronavirus, although they are likely to be protected against severe illness, and a new study suggests they also may be less contagious. At a large Israeli health maintenance organization where 650,000 members received the two-dose vaccine from Pfizer Inc and BioNTech SE, researchers identified 2,897 patients who later tested positive for COVID-19. The amounts of virus on swab samples from the nose and throat were reduced four-fold for infections occurring at least 12 days after the first dose of vaccine compared to what is typically seen in unvaccinated COVID-19 patients, the research team from Maccabi Health Services and the Technion – Israel Institute of Technology found. Viral loads are known to be linked with contagiousness and disease severity. But this study was not a randomized trial and it did not look at patients’ viral loads over time, nor the rates at which their contacts became infected, which would be the most direct evidence of whether a vaccine reduces virus transmission. Still, the authors concluded in a paper posted on Monday on the medical website medRxiv ahead of peer review, “These reduced viral loads hint to lower infectiousness, further contributing to vaccine impact on virus spread.” (https://bit.ly/2LK5HnE)
Study shows range of COVID-19 benefits from arthritis drug
A large study adds to evidence that Roche’s arthritis drug tocilizumab, sold under the brand name Actemra, cuts the risk of death among hospitalized patients with COVID-19, shortens their hospital stays and reduces their need for mechanical ventilation. The randomized trial involved more than 4,000 patients with varying degrees of illness. Some needed only simple oxygen therapy while others needed mechanical ventilation. Most also were receiving a steroid such as dexamethasone. The rate of death within 28 days was 29% for patients in the tocilizumab group and 33% in the control group, according to a report posted on Thursday on the medical website medRxiv ahead of peer review. After accounting for patients’ age, sex and other risk factors, tocilizumab was associated with a 14% reduction in the risk of death. “We now know that the benefits of tocilizumab extend to all COVID patients with low oxygen levels and significant inflammation,” study co-leader Peter Horby of the University of Oxford said in a press statement. Used in combination with steroids, Horby added, “the impact is substantial.” (https://bit.ly/3aUZhuy)
Bone marrow cells travel to brain in some COVID-19 patients
Very large bone-marrow cells are showing up in the brains of people who died of COVID-19, which may help explain some of the neurological problems associated with the disease, according to researchers. The cells, called megakaryocytes, normally reside in the bone marrow and make platelets for blood clotting. “We found that in some patients who died of COVID-19, the capillaries – the smallest blood vessels – contained very large cells called megakaryocytes,” study leader David Nauen of Johns Hopkins University told Reuters. “They are so large they could be occluding blood flow through the capillaries and limiting oxygen delivery to the brain, which could impair brain function.” As reported on Friday in the journal JAMA Neurology, his team studied brain tissue from 15 patients who died of COVID-19 and found megakaryocytes in five of their brains. “What signaled these cells to leave the bone marrow and travel to the brain is unknown, but COVID-19 causes disruptions of the clotting system, and it’s possible this is related,” Nauen said.
Open https://tmsnrt.rs/3c7R3Bl in an external browser for a Reuters graphic on vaccines in development.
(Reporting by Nancy Lapid; Editing by Will Dunham)
